PUNE, India, February 8, 2016 /PRNewswire/ --
EpiCast Report: COPD (Chronic Obstructive Pulmonary Disease) - Epidemiology Forecast to 2023 market research provides an overview of the risk factors, comorbidities, and global trends for COPD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast of the total prevalent cases of COPD and total diagnosed prevalent cases of COPD, segmented by age and sex. Additionally it provides segmentation of diagnosed prevalent cases by severity using the GOLD standard. Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM and is written and developed by Mastersand PhD-level epidemiologists.
Complete report on COPD (Chronic Obstructive Pulmonary Disease) - Epidemiology Forecast to 2023 spread across 73 pages, supported with 19 tables and 10 figures is now available at http://www.rnrmarketresearch.com/epicast-report-chronic-obstructive-pulmonary-disease-copd-epidemiology-forecast-to-2023-market-report.html .
In the 8MM, epidemiologists forecast that the total prevalent cases of COPD will increase from 64,229,605 cases in 2013 to 73,794,089 cases in 2023 at an Annual Growth Rate (AGR) of 1.49%. epidemiologists also forecast that the diagnosed prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage III, and 29.84% were in GOLD Stage IV. Epidemiologists estimated that 18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the end of the year.
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD. COPD is also a significant cause of morbidity and mortality, and the World Health Organization (WHO) predicts that it will be the third leading cause of death in the world by 2030.
Order a copy of EpiCast Report: COPD (Chronic Obstructive Pulmonary Disease) - Epidemiology Forecast to 2023 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=448334 .
Reasons to buy
The COPD EpiCast report will allow you to:-
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for COPD therapeutics in each of the markets covered.
- Identify the COPD comorbidities that are most important to your marketing plans
Another newly published market research titled Pulmonary Embolism - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects. Complete report on Pulmonary Embolism Pipeline Review market research report of 66 pages is available at http://www.rnrmarketresearch.com/pulmonary-embolism-pipeline-review-h2-2015-market-report.html .
Explore more reports on therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research